PSF1-Derived Peptides Induce CTLs for HLA-A02 Cancer Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy approaches lack effective specific treatments for HLA-A02 positive cancer patients, particularly for metastatic, chemotherapy-resistant, or recurrent cancers, as existing methods fail to induce sufficient cytotoxic T-cell responses against tumor cells.
Innovation Solution
PSF1-derived peptides with specific amino acid sequences, such as YLYDRLLRI, RALRWEYGSVLPN, and ALRWEYGSV, are identified to bind to HLA-A02 molecules on human breast cancer cells, inducing peptide-specific CTLs that can recognize and kill tumor cells, thereby enabling specific immunotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immunotherapy methods are used, then treatment is provided to cancer patients, but sufficient cytotoxic T-cell responses against tumor cells are not induced
Solution Approach 1:
The patent identifies and utilizes specific peptide sequences from PSF1 protein that exhibit high binding affinity to HLA-A02 molecules. By changing the molecular parameters (specific amino acid sequences) of the antigen, the patent achieves effective CTL induction in HLA-A02 positive cancer patients, resolving the contradiction between treatment provision and therapeutic effectiveness.
2Reliability
If PSF1-derived peptides are used for HLA-A02 positive patients, then specific CTL responses are induced, but the treatment is limited to specific HLA types
Solution Approach 1:
The patent focuses on identifying peptide sequences with specific local properties (amino acid composition and structure) that enable high-affinity binding to HLA-A02 molecules. By optimizing the local quality of the antigen peptide, the patent achieves reliable CTL induction for HLA-A02 positive patients, accepting the trade-off of limited applicability to other HLA types.
Data Source
AI summary
The purpose of the present invention is to provide a PSF1-derived peptide useful for a specific immunotherapy for cancer patients. The present invention provides: a PSF1-derived peptide which can induce a CTL; and a pharmaceutical composition for treating or preventing cancer, which contains the peptide according to the present invention.